Dementia with lewy bodies: findings from an international multicentre study
- PMID: 11113984
- DOI: 10.1002/1099-1166(200011)15:11<1034::aid-gps231>3.0.co;2-5
Dementia with lewy bodies: findings from an international multicentre study
Abstract
Objectives: To describe the baseline demographic, neuropsychiatric and neurological data of a large selected clinical sample of patients with dementia with Lewy Bodies (DLB) from an international multicentre trial with rivastigmine. To examine the usefulness of the Consensus Criteria for the diagnosis of DLB in different countries.
Methods: Seventeen centres from Spain, the UK and Italy recruited patients diagnosed clinically as probable DLB according to recent Consensus Criteria (McKeith et al., 1996). A standard clinical protocol including inclusion/exclusion criteria, collection of demographic and medical data, cognitive (Mini Mental State Examination: MMSE), motor (Unified Parkinson's Disease Rating Scale: UPDRS) and neuropsychiatric (Neuropsychiatric Inventory: NPI) examinations, was applied after obtaining informed consent. Data were summarised and compared across countries with uni- and multivariate analyses.
Results: One hundred and twenty patients were recruited: 56.7% males, mean (SD) age 73.9 (6.4) years, range 57 - 87 years. Sixty percent fulfilled all three core diagnostic features of DLB, and 40% only two ('parkinsonism' 92.4%, 'cognitive fluctuations' 89.1%, 'visual hallucinations' 77.3%). 'Systematised delusions' (46%) and 'repeated falls' (42%) were the most frequent supportive diagnostic features. There were no differences across countries in demographic, diagnostic or clinical features. Patients showed a wide range of psychopathology which was weakly correlated with cognitive impairment. Some mild extrapyramidal signs (EPS) were observed in most patients.
Conclusions: The Consensus Criteria for DLB can be consistently applied across many different sites for multicentre studies. 'Parkinsonism' and 'cognitive fluctuations' as core features and 'systematised delusions' and 'repeated falls' as supportive features are the most frequent diagnostic clues. Neuropsychiatric disturbances, in particular apathy, delusions, hallucinations and anxiety, and mild symmetric EPS are frequent in DLB and are only related weakly to cognitive impairment.
Copyright 2000 John Wiley & Sons, Ltd.
Similar articles
-
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.Lancet. 2000 Dec 16;356(9247):2031-6. doi: 10.1016/S0140-6736(00)03399-7. Lancet. 2000. PMID: 11145488 Clinical Trial.
-
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.Int J Geriatr Psychiatry. 2000 May;15(5):387-92. doi: 10.1002/(sici)1099-1166(200005)15:5<387::aid-gps131>3.0.co;2-9. Int J Geriatr Psychiatry. 2000. PMID: 10822236 Clinical Trial.
-
Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial.Int Psychogeriatr. 2001 Jun;13(2):199-205. doi: 10.1017/s104161020100758x. Int Psychogeriatr. 2001. PMID: 11495394 Clinical Trial.
-
Dementia with lewy bodies: therapeutic opportunities and pitfalls.Consult Pharm. 2006 Jul;21(7):563-75. doi: 10.4140/tcp.n.2006.563. Consult Pharm. 2006. PMID: 16934009 Review.
-
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions.Dtsch Arztebl Int. 2010 Oct;107(39):684-91. doi: 10.3238/arztebl.2010.0684. Epub 2010 Oct 1. Dtsch Arztebl Int. 2010. PMID: 20963199 Free PMC article. Review.
Cited by
-
Psychotic Disorders in Epilepsy: Do They Differ from Primary Psychosis?Curr Top Behav Neurosci. 2022;55:183-208. doi: 10.1007/7854_2021_234. Curr Top Behav Neurosci. 2022. PMID: 34426945
-
Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months.Neurology. 2021 Sep 7;97(10):e1031-e1040. doi: 10.1212/WNL.0000000000012450. Epub 2021 Aug 17. Neurology. 2021. PMID: 34404743 Free PMC article.
-
Gender and Pathology-Specific Effect of Apolipoprotein E Genotype on Psychosis in Alzheimer's Disease.Curr Alzheimer Res. 2017;14(8):834-840. doi: 10.2174/1567205014666170220150021. Curr Alzheimer Res. 2017. PMID: 28219318 Free PMC article.
-
Cognitive Impairment Evaluation and Management.Med Clin North Am. 2020 Sep;104(5):807-825. doi: 10.1016/j.mcna.2020.06.007. Med Clin North Am. 2020. PMID: 32773047 Free PMC article. Review.
-
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2. Cochrane Database Syst Rev. 2012. PMID: 22419314 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical